BlackRock reports 8.3% stake in Core Laboratories
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Core Laboratories Inc. BlackRock reports beneficial ownership of 3,811,390 shares, representing 8.3% of the common stock.
Rhea-AI Filing Summary
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Core Laboratories Inc. BlackRock reports beneficial ownership of 3,811,390 shares, representing 8.3% of the common stock. It has sole voting power over 3,703,577 shares and sole dispositive power over 3,811,390 shares, with no shared voting or dispositive power reported. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Core Laboratories’ outstanding common shares.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
parent holding company financial
Power of Attorney regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does any single BlackRock client hold more than 5% of Core Laboratories Inc (CLB)?
What dispositive power does BlackRock, Inc. report over Core Laboratories Inc (CLB) stock?
Who signed the Schedule 13G/A for BlackRock, Inc. regarding Core Laboratories Inc (CLB)?
AI-generated analysis. How Rhea-AI works. Not financial advice.